ResMed (NYSE:RMD) Director Peter Farrell Sells 2,000 Shares of Stock

ResMed Inc. (NYSE:RMD) Director Peter Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total transaction of $497,660.00. Following the sale, the director directly owned 66,773 shares of the company’s stock, valued at $16,615,125.59. The trade was a 2.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

ResMed Stock Up 0.6%

ResMed stock opened at $252.47 on Friday. The company’s 50-day moving average price is $248.44 and its two-hundred day moving average price is $263.16. The company has a quick ratio of 2.13, a current ratio of 2.89 and a debt-to-equity ratio of 0.07. The stock has a market cap of $36.84 billion, a P/E ratio of 25.84, a P/E/G ratio of 1.69 and a beta of 0.88. ResMed Inc. has a twelve month low of $199.92 and a twelve month high of $293.81.

ResMed (NYSE:RMD) last posted its earnings results on Friday, October 31st. The medical equipment provider reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.20 earnings per share. As a group, analysts expect that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Thursday, November 13th were given a dividend of $0.60 per share. The ex-dividend date was Thursday, November 13th. This represents a $2.40 annualized dividend and a yield of 1.0%. ResMed’s dividend payout ratio (DPR) is presently 24.56%.

Analysts Set New Price Targets

Several equities analysts recently commented on RMD shares. Stifel Nicolaus decreased their price target on shares of ResMed from $270.00 to $260.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Morgan Stanley set a $305.00 target price on shares of ResMed in a research report on Friday, October 31st. Mizuho lowered their target price on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Citigroup assumed coverage on ResMed in a research note on Thursday, September 18th. They issued a “buy” rating and a $330.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of ResMed in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $296.09.

Key ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Zacks Research raised multiple near‑term and multi‑year EPS forecasts for RMD, including modest bumps to Q1/Q2 2028 and FY2026–FY2028 (FY2026 to $10.62, FY2027 to $11.20 and FY2028 to $12.80). The upgrades signal analyst confidence in continued revenue and margin momentum, supporting upside to the stock.
• Neutral Sentiment: ResMed set its Q2 FY2026 earnings release for January 29, 2026 (after the NYSE close); management will host a webcast. This is a near‑term catalyst that could amplify moves depending on results and guidance. Earnings Date
• Neutral Sentiment: Recent coverage and commentary (Zacks pieces and other analyst notes) highlight ResMed as a growth name with rising device demand and expanding international sales; these narratives underpin investor interest but note macro risks.
• Neutral Sentiment: Analyst consensus remains constructive overall (MarketBeat shows a “Moderate Buy” consensus and an average target around ~$296), which can sustain buying interest into the earnings catalyst.
• Negative Sentiment: Insider selling by senior management: CEO Michael J. Farrell sold 4,991 shares at an average ~$248.46 and director Peter C. Farrell sold 2,000 shares at ~$248.83. While both retain large holdings, these disclosed sales can create short‑term nervousness about insider conviction. CEO Form 4

Institutional Trading of ResMed

Several large investors have recently made changes to their positions in RMD. Assenagon Asset Management S.A. raised its position in ResMed by 136.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 80,669 shares of the medical equipment provider’s stock valued at $19,431,000 after purchasing an additional 46,596 shares in the last quarter. Diversified Trust Co. increased its stake in shares of ResMed by 17.4% in the 4th quarter. Diversified Trust Co. now owns 1,320 shares of the medical equipment provider’s stock valued at $318,000 after purchasing an additional 196 shares during the last quarter. Wedmont Private Capital increased its stake in shares of ResMed by 2.7% in the 4th quarter. Wedmont Private Capital now owns 2,183 shares of the medical equipment provider’s stock valued at $542,000 after purchasing an additional 57 shares during the last quarter. Maridea Wealth Management LLC acquired a new position in shares of ResMed during the 4th quarter worth $378,000. Finally, Nordea Investment Management AB lifted its position in shares of ResMed by 37.2% during the 4th quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock worth $262,027,000 after buying an additional 294,124 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.